{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:04:05Z","timestamp":1785542645028,"version":"3.56.0"},"reference-count":36,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPR"],"DOI":"10.2147\/jpr.s290487","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:44:51Z","timestamp":1611863091000},"page":"249-261","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes of the Pediatric Development Plan of Tapentadol"],"prefix":"10.2147","volume":"Volume 14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4806","authenticated-orcid":true,"given":"Mari\u00eblle","family":"Eerdekens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-4567","authenticated-orcid":true,"given":"Tatjana","family":"Radic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Sohns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-4727","authenticated-orcid":true,"given":"Feras","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1724-2909","authenticated-orcid":true,"given":"Beata","family":"Bulawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-4306","authenticated-orcid":true,"given":"Christian","family":"Elling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/JPR.S195788","volume":"12","author":"Eerdekens","year":"2019","journal-title":"J Pain Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1155\/2013\/402863","volume":"18","author":"Gr\u00e9goire","year":"2013","journal-title":"Pain Res Manag"},{"key":"ref3","unstructured":"Califf RM Best Pharmaceuticals for Children Act and Pediatric Research Equity Act Status Report to Congress; 2016. Available from: https:\/\/www.fda.gov\/downloads\/scienceresearch\/specialtopics\/pediatrictherapeuticsresearch\/ucm509815.pdf. Accessed September 8, 2020."},{"key":"ref4","unstructured":"European Union. Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use, OJ L 378, 27.12;.2006. Available from: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/reg_2006_1901\/reg_2006_1901_en.pdf. Accessed September 8, 2020."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/jcph.1276","volume":"58","author":"Nafziger","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/pm\/pnw154","volume":"18","author":"Xiao","year":"2017","journal-title":"Pain Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5055\/jom.2019.0486","volume":"15","author":"Viscusi","year":"2019","journal-title":"J Opioid Manag"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/papr.12515","volume":"17","author":"Baron","year":"2017","journal-title":"Pain Pract"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40263-014-0151-9","volume":"28","author":"Tzschentke","year":"2014","journal-title":"CNS Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s12325-018-0778-x","volume":"35","author":"Raffa","year":"2018","journal-title":"Adv Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.5414\/CP201722","volume":"51","author":"G\u00f6hler","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1358\/mf.2010.32.1.1434165","volume":"32","author":"Terlinden","year":"2010","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1358\/dof.2006.031.12.1047744","volume":"31","author":"Tzschentke","year":"2006","journal-title":"Drugs Future"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/187231208783478434","volume":"2","author":"Kneip","year":"2008","journal-title":"Drug Metab Lett"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1592\/phco.30.1.25","volume":"30","author":"Smit","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.2147\/JPR.S208454","volume":"12","author":"Watson","year":"2019","journal-title":"J Pain Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.2147\/JPR.S269549","volume":"13","author":"Khalil","year":"2020","journal-title":"J Pain Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2147\/JPR.S197348","volume":"12","author":"Finkel","year":"2019","journal-title":"J Pain Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2147\/JPR.S197039","volume":"12","author":"Muse","year":"2019","journal-title":"J Pain Res"},{"key":"ref20","author":"Eissa","year":"2021","journal-title":"J Pain Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/JPR.S207010","volume":"12","author":"Beuter","year":"2019","journal-title":"J Pain Res"},{"key":"ref22","unstructured":"Electronic Medicines Compendium. Palexia oral solution 20 mg\/mL. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5346\/smpc. Accessed September 4, 2020."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.2147\/JPR.S272751","volume":"13","author":"Howard","year":"2020","journal-title":"J Pain Res"},{"key":"ref24","unstructured":"Food and Drug Administration. CDER conversations: pediatric pain management options. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/cder-conversation-pediatric-pain-management-options. Accessed December 30, 2019."},{"key":"ref25","unstructured":"Electronic Medicines Compendium. Palexia 50 mg film-coated tablets. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/28375. Accessed September 7, 2020."},{"key":"ref26","unstructured":"Electronic Medicines Compendium. Palexia SR prolonged release tablets. Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/28373. Accessed September 7, 2020."},{"key":"ref27","unstructured":"Health Products Regulatory Authority. Palexia 4 mg\/mL oral solution. Available from: https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Licence_PA2242-012-010_04032020131343.pdf. Accessed September 7, 2020."},{"key":"ref28","unstructured":"Khandelwal A, Bolger M, Brett M, Rosenburg R, Bursi R Physiologically-based pharmacokinetic (PBPK) model of tapentadol and tapentadol-O-glucuronide in adult and pediatric population. Available from: http:\/\/www.pkuk.org.uk\/Contentimages\/PKUK_2014_Programme_and_Abstractsnew.pdf. Accessed January 04, 2021."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/sim.6865","volume":"35","author":"Hlavin","year":"2016","journal-title":"Stat Med"},{"key":"ref30","unstructured":"European Medicines Agency. Reflection paper on the use of extrapolation in the development of medicines for paediatrics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf. Accessed September 7, 2020."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5812\/aapm.4092","volume":"2","author":"Hosseini Jahromi","year":"2012","journal-title":"Anesth Pain Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0300-5712(94)90084-1","volume":"22","author":"Urquhart","year":"1994","journal-title":"J Dent"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1542\/peds.2010-3591","volume":"129","author":"Berde","year":"2012","journal-title":"Pediatrics"},{"key":"ref34","unstructured":"European Medicines Agency. 10-year report to the European Commission - general report on the experience acquired as a result of the application of the Paediatric Regulation. Available from: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/paediatrics\/docs\/paediatrics_10_years_ema_technical_report.pdf. Accessed September 7, 2020."},{"key":"ref35","unstructured":"European Medicines Agency. European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/report\/european-medicines-agency-european-commission-dg-health-food-safety-action-plan-paediatrics_en.pdf. Accessed September 8, 2020."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5055\/jom.2013.0171","volume":"9","author":"Zannikos","year":"2013","journal-title":"J Opioid Manag"}],"container-title":["Journal of Pain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=66116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=66116","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:45:23Z","timestamp":1611863123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/outcomes-of-the-pediatric-development-plan-of-tapentadol-peer-reviewed-article-JPR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":36,"URL":"https:\/\/doi.org\/10.2147\/jpr.s290487","relation":{},"ISSN":["1178-7090"],"issn-type":[{"value":"1178-7090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}